Findings

What do systematic reviews say?

14 questions · 14 findings · 2 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 12 · 85.7%High 2 · 14.3%

Fondaparinux vs placebo

Symptomatic VTE · people with ST of the leg

Fondaparinux probably leads to lower symptomatic VTE Ventilation‐perfusion scanning, helical computed… compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
RR 0.15 [0.04, 0.5]
1 study · 3002 participants
Moderate

Fondaparinux vs placebo

Major bleeding · people with ST of the leg

Fondaparinux showed no clear difference in major bleeding compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
RR 0.99 [0.06, 15.86]
1 study · 2987 participants
Moderate

Fondaparinux vs placebo

Extension of ST Ultrasonography · people with ST of the leg

Fondaparinux probably leads to lower extension of ST Ultrasonography compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
RR 0.08 [0.03, 0.22]
1 study · 3002 participants
Moderate

Fondaparinux vs placebo

Recurrence of ST Ultrasonography · people with ST of the leg

Fondaparinux probably leads to lower recurrence of ST Ultrasonography compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
RR 0.21 [0.08, 0.54]
1 study · 3002 participants
Moderate

Fondaparinux vs placebo

All‐cause mortality · people with ST of the leg

Fondaparinux showed no clear difference in mortality compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
RR 2 [0.18, 22]
1 study · 3002 participants
Moderate

Fondaparinux vs placebo

Minor bleeding · people with ST of the leg

Fondaparinux showed no clear difference in minor bleeding compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
RR 1.49 [0.53, 4.17]
1 study · 2987 participants
Moderate

Fondaparinux vs placebo

Adverse effects of treatment · people with ST of the leg

Fondaparinux showed no clear difference in adverse effects of treatment compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for superficial thrombophlebitis of the leg 2018 · Cochrane Headline outcomes only
RR 1.13 [0.78, 1.65]
1 study · 2987 participants
Moderate

Fondaparinux vs placebo

Total VTE · people requiring prevention of venous thromboembolism

Fondaparinux probably leads to lower total VTE compared with placebo (moderate certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 0.24 [0.15, 0.38]
8 studies · 5717 participants
Moderate

Fondaparinux vs placebo

Symptomatic VTE · people requiring prevention of venous thromboembolism

Fondaparinux leads to lower symptomatic VTE compared with placebo (high certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 0.15 [0.06, 0.36]
8 studies · 6503 participants
High

Fondaparinux vs placebo

Deep vein thrombosis · people requiring prevention of venous thromboembolism

Fondaparinux probably leads to lower total DVT compared with placebo (moderate certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 0.25 [0.15, 0.4]
8 studies · 5715 participants
Moderate

Fondaparinux vs placebo

Proximal DVT · people requiring prevention of venous thromboembolism

Fondaparinux probably leads to lower proximal DVT compared with placebo (moderate certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 0.12 [0.04, 0.39]
7 studies · 2746 participants
Moderate

Fondaparinux vs placebo

Total PE · people requiring prevention of venous thromboembolism

Fondaparinux leads to lower total PE compared with placebo (high certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 0.16 [0.04, 0.62]
8 studies · 6412 participants
High

Fondaparinux vs placebo

Major bleeding · people requiring prevention of venous thromboembolism

Fondaparinux probably leads to higher major bleeding compared with placebo (moderate certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 2.56 [1.48, 4.44]
8 studies · 6659 participants
Moderate

Fondaparinux vs placebo

All causes of death · people requiring prevention of venous thromboembolism

Fondaparinux showed no clear difference in all causes of death compared with placebo (moderate certainty).

1 finding from 1 review

Pentasaccharides for the prevention of venous thromboembolism 2016 · Cochrane Headline outcomes only
RR 0.76 [0.48, 1.22]
8 studies · 6674 participants
Moderate